Bacterial Coverage of Unasyn (Ampicillin-Sulbactam)
Unasyn (ampicillin-sulbactam) provides broad-spectrum coverage against gram-positive, gram-negative, and anaerobic bacteria, including beta-lactamase producing organisms. The combination effectively extends ampicillin's spectrum by adding sulbactam, which irreversibly inhibits many clinically important beta-lactamases.
Spectrum of Activity
Gram-Positive Bacteria
- Staphylococcus species (including beta-lactamase producing strains)
- Staphylococcus aureus (methicillin-susceptible)
- Staphylococcus saprophyticus
- Streptococcus species
- Streptococcus pneumoniae
- Streptococcus pyogenes
- Streptococcus viridans group
- Enterococcus faecalis
Gram-Negative Bacteria
- Haemophilus influenzae (beta-lactamase and non-beta-lactamase producing)
- Moraxella catarrhalis (formerly Branhamella catarrhalis)
- Escherichia coli (beta-lactamase and non-beta-lactamase producing)
- Klebsiella species
- Proteus species (mirabilis and vulgaris)
- Providencia species (rettgeri and stuartii)
- Morganella morganii
- Neisseria gonorrhoeae
- Acinetobacter species
Anaerobic Bacteria
- Bacteroides species, including Bacteroides fragilis
- Clostridium species
- Peptococcus species
- Peptostreptococcus species
Clinical Applications
Unasyn is particularly valuable in treating:
- Mixed infections where both aerobic and anaerobic coverage is needed 1
- Intra-abdominal infections 2
- Skin and soft tissue infections, particularly animal and human bites 2
- Gynecological infections including PID 2
- Urogenital tract infections 3, 4
Important Considerations
- Unasyn does not cover MRSA, Pseudomonas aeruginosa, or extended-spectrum beta-lactamase (ESBL) producing organisms
- For serious infections, the typical dosage is 3g IV every 6 hours 2
- When treating polymicrobial infections, Unasyn provides better anaerobic coverage than cephalosporins alone 2
- For animal and human bites, Unasyn is specifically recommended for intravenous treatment 2
Advantages Over Other Agents
Ampicillin-sulbactam has several advantages over using metronidazole plus another agent:
- It provides single-agent coverage for mixed infections
- Unlike metronidazole, which requires combination with agents effective against gram-positive cocci 5, Unasyn inherently covers both gram-positive and anaerobic organisms
- It demonstrates bactericidal activity against a wide range of pathogens 6
Limitations
- Not effective against ESBL-producing organisms
- Limited activity against Pseudomonas species
- Not effective against MRSA
- Pain at injection site is a common adverse effect with intramuscular administration 4
For empiric treatment of polymicrobial infections, Unasyn provides excellent broad-spectrum coverage and is particularly valuable when both aerobic and anaerobic pathogens are suspected.